Next Article in Journal
Management of Hot Flashes in Women with Breast Cancer
Previous Article in Journal
Cost Effectiveness of tac versus fac in Adjuvant Treatment of Node-Positive Breast Cancer
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Article

Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic

1
Centre for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology, Nonakuri, Purba Medinipur WB-721172, India
2
Maharani Lakshmi Ammanni College for Women, Bangalore University, Malleshwaram, Bangalore, India
3
Functional Genomics Unit, Institute of Genomics and Integrative Biology, Council of Scientific and Industrial Research, Delhi, India
*
Author to whom correspondence should be addressed.
Received: 4 November 2009 / Revised: 3 December 2009 / Accepted: 6 January 2010 / Published: 1 February 2010
In recent years, various rna-based technologies have been under evaluation as potential next-generation cancer therapeutics. MicroRNAS (miRNAS), known to regulate the cell cycle and development, are deregulated in various cancers. Thus, they might serve as good targets or candidates in an exploration of anticancer therapeutics. One attractive candidate for this purpose is let-7 (“lethal-7”). Let-7 is underexpressed in various cancers, and restoration of its normal expression is found to inhibit cancer growth by targeting various oncogenes and inhibiting key regulators of several mitogenic pathways. In vivo, let-7 administration was found effective against mouse-model lung and breast cancers, and our computational prediction supports the possible effectiveness of let-7 in estrogen receptor (ER)–positive metastatic breast cancer. Data also suggest that let-7 regulates apoptosis and cancer stem cell (CSC) differentiation and can therefore be tested as a potential therapeutic in cancer treatment. However, the exact role of let-7 in cancer is not yet fully understood. There is a need to understand the causative molecular basis of let-7 alterations in cancer and to develop proper delivery systems before proceeding to therapeutic applications. This article attempts to highlight certain critical aspects of let-7’s therapeutic potential in cancer.
Keywords: Let-7; microrna; cancer therapy; let-7 regulation; future medicine Let-7; microrna; cancer therapy; let-7 regulation; future medicine
MDPI and ACS Style

Barh, D.; Malhotra, R.; Ravi, B.; Sindhurani, P. Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic. Curr. Oncol. 2010, 17, 70-80. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.356

AMA Style

Barh D, Malhotra R, Ravi B, Sindhurani P. Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic. Current Oncology. 2010; 17(1):70-80. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.356

Chicago/Turabian Style

Barh, D., R. Malhotra, B. Ravi, and P. Sindhurani 2010. "Microrna Let-7: An Emerging Next-Generation Cancer Therapeutic" Current Oncology 17, no. 1: 70-80. https://0-doi-org.brum.beds.ac.uk/10.3747/co.v17i1.356

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop